Koru Medical Systems, Inc. income statement
In fiscal 2025, Koru Medical Systems, Inc. reported revenue of $41.1m, up 22.2% on the year before, operating income of −$3.0m (a -7.2% margin) and net income of −$2.6m, or −$0.06 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2011Feb 2011 | 2012Feb 2012 | 2013Feb 2013 | 2014Feb 2014 | 2015Feb 2015 | 2016Feb 2016 | 2017Feb 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 6 | 8 | 9 | 11 | 12 | 12 | 17 | 23 | 24 | 23 | 28 | 29 | 34 | 41 | 45 |
| Cost of revenue | — | — | — | — | — | — | — | 7 | 8 | 9 | 10 | 13 | 12 | 12 | 16 | 17 |
| Gross profit | — | — | — | 5 | 7 | 8 | 8 | 11 | 15 | 15 | 14 | 15 | 17 | 21 | 26 | 28 |
| Research and development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 5 | 6 | 5 | 4 | 4 |
| Selling, general and administrative | 2 | 3 | 4 | 4 | 5 | 6 | 8 | 8 | 10 | 12 | 18 | 21 | 20 | 22 | 23 | 25 |
| Operating income | 1 | 1 | 1 | 1 | 1 | 1 | −1 | 1 | 1 | −1 | −7 | −11 | −10 | −6 | −3 | −2 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — |
| Provision for credit losses | — | — | — | — | — | — | — | −0 | −0 | −0 | — | — | — | — | — | — |
| Income before tax | 1 | 1 | 1 | 1 | 1 | 1 | −1 | 1 | 1 | 1 | −6 | −11 | −10 | −6 | −3 | −2 |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 | −0 | −2 | −2 | 4 | 0 | 0 | — |
| Net income | 1 | 1 | 1 | 1 | 1 | 1 | −1 | 1 | 1 | −1 | −5 | −9 | −14 | −6 | −3 | −2 |
| Diluted EPS | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | −$0.01 | $0.02 | $0.01 | −$0.03 | −$0.10 | −$0.19 | −$0.30 | −$0.13 | −$0.06 | −$0.04 |
| Diluted shares (average) | 37m | 35m | 36m | 37m | 38m | 38m | 38m | 39m | 39m | 42m | 44m | 45m | 46m | 46m | 46m | 47m |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 1 | −0 | 1 | 1 | −1 | −7 | −10 | −9 | −6 | −2 | −1 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8 | 9 | 10 | 10 | 10 | 11 | 12 | 12 |
| Cost of revenue | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 4 |
| Gross profit | 5 | 6 | 6 | 6 | 6 | 7 | 7 | 8 |
| Research and development | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 5 | 6 | 6 | 5 | 6 | 6 | 7 | 6 |
| Operating income | −2 | −2 | −1 | −0 | −1 | −1 | −1 | 1 |
| Income before tax | −2 | −2 | −1 | −0 | −1 | −0 | −1 | 0 |
| Income tax | — | — | — | 0 | −0 | 0 | — | 0 |
| Net income | −2 | −2 | −1 | −0 | −1 | −0 | −1 | 0 |
| Diluted EPS | $0.03 | −$0.23 | −$0.03 | $0.00 | $0.02 | −$0.11 | −$0.02 | $0.01 |
| EBITDA | −1 | −1 | −1 | −0 | −1 | −0 | −1 | 1 |
Compare with peers
- Trisalus Life Sciences, Inc. income statement
- Clearpoint Neuro, Inc. income statement
- Sanuwave Health, Inc. income statement
- Myomo, Inc. income statement
- Senseonics Holdings, Inc. income statement
Head to head: KRMD vs TLSICLPT vs KRMDKRMD vs SNWVKRMD vs MYO
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies